Trial Profile

Fecal Microbiota Transplantation Combined With QL1706, Bevacizumab, and XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis: A Prospective, Multi-center, Single-arm Phase II Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Iparomlimab/tuvonralimab (Primary) ; Oxaliplatin (Primary)
Indications Colon cancer; Liver metastases
Focus Therapeutic Use

02 Jan 2026 Status changed from not yet recruiting to recruiting.
03 Sep 2025 Planned initiation date changed from 30 Jul 2025 to 15 Sep 2025.
29 Jul 2025 Planned initiation date changed from 30 Jun 2025 to 30 Jul 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com